Profiles of Multidrug Resistance Protein-1 in the Peripheral Blood Mononuclear Cells of Patients with Refractory Epilepsy

Jae-Jun Ban1,2,3*, Keun-Hwa Jung1,2,3*, Kon Chu1,2,3*, Soon-Tae Lee1,2,3, Daejong Jeon4, Kyung-II Park5, Hye-Jin Moon1, Hyeyun Kim6, Sunghun Kim7, Sang Kun Lee1,2,3*, Jae-Kyu Roh1,2,3

1 Department of Neurology, Laboratory for Neurotherapeutics, Seoul National University Hospital, Seoul, South Korea, 2 Program in Neuroscience, Neuroscience Research Institute of SNUMRC, Seoul National University, Seoul, South Korea, 3 Comprehensive Epilepsy Center, Seoul National University Hospital, Seoul, South Korea, 4 Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea, 5 Departments of Neurology, Inje University Balk Hospital, Seoul, South Korea, 6 Kwandong University Myongji Hospital, Goyang, South Korea, 7 Gangwon National University College of Medicine, Chuncheon, South Korea

Abstract

Background: About one third of patients with epilepsy become refractory to therapy despite receiving adequate medical treatment, possibly from multidrug resistance. P-glycoprotein, encoded by multidrug resistance protein-1 (MDR1) gene, at the blood brain barrier is considered as a major factor mediating drug efflux and contributing to resistance. Given that peripheral blood mononuclear cells (PBMCs) express MDR1, we investigated a MDR1 status of PBMCs in various subsets of epilepsy patients and demonstrated their association with clinical characteristics.

Methodology/Principal Findings: Clinical and MDR1 data were collected from 140 patients with epilepsy, 30 healthy volunteers, and 20 control patients taking anti-epileptic drugs. PBMCs were isolated, and basal MDR1 levels and MDR1 conformational change levels were measured by flow cytometry. MDR1 profiles were analyzed according to various clinical parameters, including seizure frequency and number of medications used in epilepsy patients. Epilepsy patients had a higher basal MDR1 level than non-epilepsy groups (p<0.01). Among epilepsy patients, there is a tendency for higher seizure frequency group to have higher basal MDR1 level (p=0.059). The MDR1 conformational change level was significantly higher in the high-medication-use group than the low-use group (p = 0.028). Basal MDR1 (OR = 1.16 [95% CI: 1.060–1.268]) and conformational change level (OR = 1.11 [95% CI: 1.02–1.20]) were independent predictors for seizure frequency and number of medications, respectively.

Conclusions/Significance: The MDR1 profile of PBMCs is associated with seizure frequency and medication conditions in patients with epilepsy.

Introduction

Almost one-third of patients with epilepsy cannot achieve seizure freedom and have a poor prognosis despite receiving adequate medical treatment and the administration of multiple anti-epileptic drugs (AEDs) [1]. Although the mechanism of this refractoriness remains unclear, the prediction of medically refractory epilepsy is an important concern of current epilepsy research.

Multidrug resistance protein-1 (MDR1), multidrug resistance-related proteins and breast cancer resistance proteins comprise members of the multidrug resistance protein family. MDR1, first known as a drug-resistance protein in tumor cells [2], is a 170- to 180-kDa membrane protein. MDR1 mediates ATP-dependent drug efflux for various xenobiotics and drugs [3,4].

The apical membranes of capillary endothelial cells of the blood-brain barrier express MDR1, which contributes to drug efflux from the brain to the systemic circulation. Despite the protective role of transporter proteins, AED penetration to the brain is compromised by MDR1 [5–7]. For intractable patients with epilepsy, drug resistance is likely caused by a high level of MDR1 in the brain endothelium [8–10].

Recent studies suggest that molecular profile of peripheral blood mononuclear cells (PBMCs) could be used as biopsy material to reflect physiological condition of the body and a possible marker for predicting the treatment outcome of various diseases [11–17]. Given that human peripheral blood cells also express MDR1 proteins and play a role in brain endothelial cell turnover [18], we
hypothesized that the MDR1 profile of these cells might be related to drug resistance of epilepsy.

In this study, we examined epilepsy patients, healthy volunteers, and non-epilepsy patients taking AEDs. We also divided refractory epilepsy patients according to their seizure frequency and the number of medications required to control their seizures, which could be regarded as criteria of refractoriness of epilepsy [1,19]. For MDR1 status, we examined basal MDR1 level and conformational change level of PBMCNs by flow cytometry. Both the basal MDR1 level and conformational change level were measured using the UIC2 antibody, which binds to the MDR1 protein and has high affinity to the activated ATP-hydrolyzing form of MDR1 in the presence of substrate [20,21]. The enhanced affinity of this antibody allows for detection of cells with relatively low MDR1 expression. The basal MDR1 level, which was analyzed by a conventional flow cytometry after staining unstimulated PBMCNs, reflects the number of cells expressing high level of MDR1 protein. The MDR1 conformational change level measured in vinblastine-treated PBMCNs, which have activated MDR1, reflects the number of all cells with functional MDR1 which has the ability of actual pumping action in peripheral blood [22,23]. Several clinical parameters were assessed in association with the categorized MDR1 data.

Materials and Methods

Ethics Statement

The study protocol was approved by the Scientific Review Committee and the Institutional Review Board of Seoul National University Hospital, and all enrolled subjects provided written informed consent as required by the Declaration of Helsinki.

Study Population

We studied 117 refractory and 23 seizure-free epilepsy patients who were diagnosed with temporal lobe epilepsy, and 20 control patients taking AEDs. The seizure-free epilepsy patients didn’t experience seizure for at least one year. The control with AEDs consisted of non-epilepsy patients taking AEDs because of neuropathic pain, headache and etc. The patients underwent medical follow-up at the Department of Neurology, Seoul National University Hospital, from February 2008 to December 2010. Thirty healthy volunteers were recruited for the control group. A questionnaire was developed by the authors to evaluate the patients’ demographic data and medical histories.

PBMCN Preparation and Flow-cytometric Analysis

Materials for the flow cytometry staining including MDR1 antibody (UIC2 antibody), dimethyl sulfoxide (DMSO), vinblastine, working solutions, and binding buffers were all included in the MDR1 shift assay kit (Chemicon International, Temecula, CA, USA). Peripheral blood samples (5cc) were obtained from all enrolled subjects. The heparinized blood samples were added to Histopaque (Sigma-Aldrich, St. Louis, MO, USA) and centrifuged at 400 × g for 5 min. The supernatant was removed, and the pellets were resuspended to 1 × 10^6 cells/mL in warmed UIC2 binding buffer (1% bovine serum albumin in PBS). Basal MDR1 level assay procedure is as follows: cells were divided into two groups and treated with 5 μL of DMSO respectively. The tubes were incubated at 37°C for 10 min; 25 μL of the kit’s IgG2a antibody working solution was added to one group and 25 μL of UIC2 antibody working solution was added to the other group. The tubes were incubated at 37°C for another 15 min and washed three times with cold UIC2 binding buffer at 200 × g for 10 min at 4°C. The cells were resuspended in 250 μL ice-cold secondary antibody working solution and incubated for 15 min at 4°C in the dark. After being washed three times, the cells were resuspended in 0.5 mL ice-cold propidium iodide staining buffer. Samples were then maintained on ice until analysis with a flow cytometer (FACSCalibur, BD Biosciences, San Jose, CA, USA), using FL2 channel for indirect UIC2 staining and FL3 channel for propidium iodide to exclude dead cells. To filter out cell debris, forward scatter and side scatter of the cells were measured and lymphocytes and monocytes regions were gated (Fig. 1A). After gating cell populations, propidium iodide negative cells were gated to wipe out dead cells (Fig. 1B); Using this cell population, baseline for gating positive population was confirmed using IgG2a isotype. UIC2 positive populations were gated using this baseline and positive cell number was counted using FL2 channel (Fig. 1C). Positive level was calculated as a percentage of UIC2 positive cell number in whole live cell population. For MDR1 conformational change level assay, we used 5 μL of 22 mM vinblastin instead of DMSO and rest of the process is identical to basal MDR1 level. UIC2 antibody reacts with membrane bound MDR1 and their reactivity

Figure 1. Analysis of MDR1 profiles of PBMCNs with the flow cytometry. (A) PBMCNs were stained with MDR1 antibody and propidium iodide (PI) and examined forward scatter (FSC) and side scatter (SSC) and leukocytes were gated (R1) to exclude aggregates and debris. (B) In R1 gated population, PI positive dead cells were excluded and PI negative live cells were gated (lined box). (C) In gated cells, the MDR1-positive population was assessed using the baseline determined from a negative control of IgG2a background staining (dotted box). (D) Representative histogram figures show the basal MDR1 level (left) and conformational change level (right).

doi:10.1371/journal.pone.0036985.g001
is increased when conformational change of MDR1 occurs. The basal MDR1 level reflects the number of cells expressing high level of MDR1 and the conformational change level reflects all functional MDR1 level in PBMNCs [22, 23].

Statistical Analysis

Data were analyzed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Student’s t-test or analysis of variance with subsequent Tukey’s b-test for MDR1 conformational change level, Mann-whitney U test or Kruskal-Wallis test for basal MDR1 level were used to compare mean values for continuous variables, and the chi-squared test was used for categorical variables. We classified refractory epilepsy patients in terms of seizure frequency. The low-frequency group had fewer than one seizure per week (n = 69, 59%) and the high-frequency group had one or more seizures per week (n = 48, 41%). We also classified the patients into those taking three or more medications (n = 63, 54%) and those taking fewer than three (n = 54, 46%). To identify factors helping to predict high seizure frequency and medication number, multiple logistic regression analysis was performed with significant variables defined from the initial univariate analysis, and statistical significance was set at p < 0.05.

Results

Patient Characteristics

The study was carried out in 190 subjects, including 117 refractory epilepsy patients, 23 seizure-free epilepsy patients, 30 healthy volunteers, and 20 control patients taking AEDs. The baseline characteristics of the refractory epilepsy patients are summarized in Table 1. Characteristics, including age, number of AEDs and type of AEDs, of control groups are represented in Table 2.

MDR1 Profiles Among Patients

The basal MDR1 and conformational change level of MDR1 in the PBMNCs were analyzed using flow cytometry. Representative superimposed histograms of basal MDR1 level and conformational change level are presented (Fig. 1D). Kruskal-Wallis test confirmed significant differences in the basal MDR1 levels among groups (p < 0.01). Patients with epilepsy had higher basal MDR1 levels than the healthy volunteers and control patients taking AEDs (p < 0.01; Fig. 2A). The conformational change level was not significantly different among groups (Fig. 2B).

MDR1 Profiles According to Seizure Frequency

We classified refractory patients into high- and low-seizure-frequency groups (Table 3). The high-frequency group took more medications (3.2 ± 1.4 vs. 2.6 ± 1.7, p = 0.015) than the low-frequency group. The high-frequency group tended to have a higher basal MDR1 level (9.7 ± 6.2% vs. 7.2 ± 4.0%, p = 0.059) (Fig. 2C). Moreover, independent associations with seizure frequency were noted for basal MDR1 level (p = 0.001), number of medications (p = 0.022), and a history of temporal lobectomy (p = 0.004). The odds ratio of the basal MDR1 level for seizure frequency was 1.160 (95% CI, 1.060–1.268) after adjustment (Table 4).

MDR1 Profiles According to AED Intake

To evaluate the association between the MDR1 profile and drug resistance, we categorized patients into high- and low-
medication-use groups. All variables and statistical data are shown in Table 5. The high-medication group had a younger age of onset and a longer duration of epilepsy (17.6±13.2 vs. 23.3±13.1 years, p = 0.02; 20.6±10.8 vs. 13.5±10 years, p < 0.05) (Fig. 2D). The mean seizure frequency tended to be higher in the high-medication group, but it was not significant. In terms of MDR1 status, we found a higher conformational change level in the high-medication group than in the low-medication group (p = 0.028), whereas basal MDR1 level was not significantly different between these groups. Multiple logistic regression analysis indicated that the duration of epilepsy and the conformational change level were significant independent predictors of the number of AEDs taken (Table 4). The odds ratio of conformational change level of MDR1 for medication number was 1.11 (95% CI, 1.02–1.20).

Discussion

We assayed the MDR1 profile of PBMNCs in epilepsy patients by flow cytometry. We categorized 117 patients with refractory epilepsy according to seizure frequency and the number of medications taken. These two parameters could be regarded as criteria for the severity of refractoriness [19,24]. Basal MDR1 level and conformational change level were higher in the high-seizure frequency group and high-medication group, respectively. Multiple logistic regression analysis revealed these as independently related factors.

Our results suggested that the basal MDR1 level was higher in epilepsy patients compared with healthy volunteers and non-epilepsy patients taking AEDs. The AEDs were administered to non-epilepsy patients for treatment of migraine, neuropathic pain, and etc. The regimens included valproic acid, topiramate or pregabalin, and their dosage ranges were much lower than those

![Figure 2. MDR1 profiles among groups and refractory epilepsy patients.](image-url) Graphs represent (A) basal MDR1 level and (B) conformational change level among the groups. Graphs represent (C) basal MDR1 level between low- and high-seizure-frequency groups and (D) conformational change level between low- and high-medication-use groups in the refractory epilepsy patients. The horizontal lines represent the median level and standard error of the mean.

doi:10.1371/journal.pone.0036985.g002

### Table 3. Correlation between seizure frequency and clinical parameters.

| Parameters                      | Seizure frequency |   | p Value |
|---------------------------------|-------------------|---|---------|
|                                 | Low (n = 69)      | High (n = 48) |         |
| Frequency of seizure (per week) | 0.1±0.2           | 4.6±5.6       | <0.001  |
| Age (year)                      | 38±11             | 37.5±10.7     | 0.817   |
| Age of onset (year)             | 20.8±13.2         | 19.5±13.7     | 0.632   |
| Duration of epilepsy (year)     | 17±11.8           | 17.7±10       | 0.752   |
| Number of AEDs                  | 2.6±1.2           | 3.2±1.4       | 0.015*  |
| Seizure duration (sec)          | 118.8±172.0       | 98.6±150.4    | 0.515   |
| BMI                             | 35.8±7.6          | 34.3±8.9      | 0.323   |
| Hypertension: n (%)             | 5 (7.2)           | 5 (10.4)      | 0.738   |
| Diabetes: n (%)                 | 0 (0)             | 3 (6.3)       | 0.066   |
| Hyperlipidemia: n (%)           | 0 (0)             | 1 (2.1)       | 0.410   |
| Smoking: n (%)                  | 7 (10.1)          | 7 (14.6)      | 0.467   |
| Temporal lobectomy: n (%)       | 3 (4.3)           | 7 (14.6)      | 0.089   |
| Febrile seizure: n (%)          | 16 (23.2)         | 3 (6.3)       | 0.015*  |
| Family history: n (%)           | 4 (5.8)           | 4 (8.3)       | 0.715   |
| Semiology: (GTCS: CPS: SPS,%    | 58.2: 23.9: 17.9  | 55.6: 26.7: 17.8 | 0.943   |
| Basal MDR1 level (%)            | 7.2±4.0           | 9.7±6.2       | 0.009** |
| Conformational change level (%) | 14.2±5.2          | 14.9±6.0      | 0.512   |

BMI = body mass index.

*p < 0.05, **p < 0.01.

doi:10.1371/journal.pone.0036985.t003
in the refractory epilepsy patients. The lower dosage range and different type of anticonvulsants could influence lower MDR1 level of PBMNCs in non-epilepsy with AEDs than epilepsy with AEDs. However, we found no significant difference according to the types of AEDs among epilepsy patients. In this study, the high-seizure-frequency group also took more medications. This group experienced recurrent seizures despite adequate administration of multiple AEDs. Although these drugs control seizures initially, drug resistance may gradually emerge from the overexpression of MDR1, leading to refractory epilepsy [25]. Our result shows that drug resistance may gradually emerge from the overexpression of multiple AEDs. However, we found no significant difference according to different type of anticonvulsants could influence lower MDR1 level of PBMNCs in non-epilepsy with AEDs than epilepsy with AEDs.

| Parameters          | Low (n = 54) | High (n = 63) | p Value |
|---------------------|-------------|--------------|---------|
| Number of AEDs      | 1.6 ± 0.4   | 3.9 ± 0.9    | <0.001  |
| Age (year)          | 37.4 ± 11.6 | 38.2 ± 10.2  | 0.174   |
| Age of onset (year) | 23.3 ± 13.1 | 17.6 ± 13.2  | 0.020*  |
| Duration of epilepsy (year) | 13.5 ± 10.1 | 20.6 ± 10.8  | <0.001**|
| Frequency of seizure (per week) | 1.2 ± 2.7  | 2.2 ± 5.7    | 0.246   |
| Seizure duration (sec) | 146.4 ± 200.1 | 78.9 ± 114.5 | 0.033*  |
| BMI                 | 34.8 ± 7.7  | 35.5 ± 8.5   | 0.650   |
| Hypertension: n (%) | 3 (5.6)     | 7 (11.1)     | 0.337   |
| Diabetes: n (%)     | 1 (1.9)     | 2 (3.2)      | 1       |
| Hyperlipidemia: n (%)| 0 (0)       | 1 (1.6)      | 1       |
| Smoking: n (%)      | 6 (11.1)    | 8 (12.7)     | 0.792   |
| Temporal lobectomy: n (%) | 4 (7.4)  | 6 (9.5)      | 0.751   |
| Febrile seizure: n (%) | 7 (13)     | 12 (19)      | 0.374   |
| Family history: n (%) | 4 (7.4)    | 4 (6.3)      | 1       |
| Semiology: (GTCS: CPS: SP5%) | 58.5±22.6:18.9:55.9:27:16:9.1 | 55.9±27:1:16:9.1 | 0.855   |
| Basal MDR1 level (%) | 8.5±5.1   | 8.0±5.2     | 0.634   |
| Conformational change level (%) | 13.3±4.6 | 15.7±6.3    | 0.028*  |

*p<0.05,  **p<0.01. doi:10.1371/journal.pone.0036985.t005

Table 5. Correlation between medication number and clinical parameters.
References

1. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. (2007) Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62: 302–319.

2. Gros P, Ben Neriah YB, Croop JM, Housman DE. (1986) Expression and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728–731.

3. Fromm MF. (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423–429.

4. Schinkel AH, Jonker JW. (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3–29.

5. Loscher W, Potschka H. (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76: 22–76.

6. Robey RW, Lazarowski A, Bates SE. (2008) P-glycoprotein—a clinical target in drug-refractory epilepsy? Mol Pharmacol 73: 1343–1346.

7. Zimprich F, Sunder-Plassmann R, Sogstann G, Gleiss A, Dal-Bianco A, et al. (2004) Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63: 1087–1089.

8. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, et al. (2001) Expression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42: 1501–1506.

9. Lazarowski A, Czornysz L, Lubienicki F, Girardi E, Vazquez S, et al. (2001) Overexpression of multidrug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42: 1501–1506.

10. Tishler DM, Weinberg KI, Hinton DR, Barney N, Annett GM, et al. (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1–6.

11. Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, et al. (2000) Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 67: 49–50.

12. Grude P, Bolejasko E, Comi F, Czuchrovksy S, Calman Y. (2002) MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. Transplantation 73: 1824–1828.

13. Senent L, Jarque I, Martin G, Sempere A, Gonzalez-Garcia Y, et al. (1998) P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica 83: 783–787.

14. Tsujimura S, Santo K, Nakayamada S, Tanaka Y. (2007) Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus. Histol Histopathol 22: 465–468.

15. Mohs R, Liew CC. (2007) The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 13: 422–432.

16. Turriziani O, Giniotti N, Falsa F, Boni A, Vestri AR, et al. (2008) Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol 80: 766–771.

17. Karsten SL, Kado LC, Bragin AJ. (2011) Use of peripheral blood transcriptome biomarkers for epilepsy prediction. Neurosci Lett 497: 213–217.

18. Hill JM, Zales G, Halcox JP, Schenke WH, Wacławski MA, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593–600.

19. Beleza P. (2009) Refractory epilepsy: a clinically oriented review. Eur Neurol 62: 65–71.

20. Colnot EM, Baldes C, Scharfer UF, Edgar KJ, Wempe MF, et al. (2010) P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci U S A 94: 12908–12913.

21. Druley TE, Stein WD, Ruth A, Roninson IB. (2001) P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation. Biochemistry 40: 4323–4331.

22. Luna-Tortos C, Fedrowitz M, Loscher W. (2008) Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55: 298: H1687–1698.

23. Vilas-Boas V, Silva R, Garcia AR, Martins AM, Lima SC, et al. (2011) P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A 79: 912–919.

24. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, et al. (2009) Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51: 1364–1375.

25. van Vliet EA, Edelbroek PM, Gorter JA. (2010) Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats. Epilepsia 51: 362–370.

26. Luna-Tortos C, Fedrowitz M, Loscher W. (2008) Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55: 1364–1375.

27. Zhang Q, Kwan P, Zuo Z, Baum L. (2011) The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev.

28. Collnot EM, Baldes C, Scharfer UF, Edgar KJ, Wempe MF, et al. (2010) P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation. Biochemistry 40: 4323–4331.

29. Langer O, Bauer M, Hammers A, Karch R, Pataraia E, et al. (2007) Improved seizure control by oral coadministration of antiepileptic agents: a pilot study. Epilepsia 48 Suppl 5: 140–149.

30. Parfenova H, Leffler CW, Tcheranova D, Basuroy S, Zimmermann A. (2010) The transport of antiepileptic drugs: A systematic review. Epilepsia 51: 1364–1375.

31. Vilas-Boas V, Silva R, Garcia AR, Martins AM, Lima SC, et al. (2011) P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A 79: 912–919.